“Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Chimpanzee Adenovirus Vector Ebola Vaccine.”, N Engl J Med, vol. 376, no. 10, pp. 928-938, 2017.
, “Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli”, Lancet Infect Dis, vol. 16, no. 1, pp. 31-42, 2016.
, ,
“Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.”, PLoS One, vol. 9, no. 9, p. e106240, 2014.
, “Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).”, PLoS One, vol. 9, no. 3, p. e91366, 2014.
, “DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.”, PLoS One, vol. 8, no. 4, p. e59340, 2013.
, “Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.”, Science, vol. 341, no. 6152, pp. 1359-65, 2013.
, “Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.”, J Infect Dis, vol. 207, no. 12, pp. 1829-40, 2013.
, “Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.”, PLoS One, vol. 5, no. 2, p. e9015, 2010.
, “A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.”, Vaccine, vol. 26, no. 50, pp. 6338-43, 2008.
, “Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.”, Vaccine, vol. 25, no. 20, pp. 4085-92, 2007.
, “Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.”, Vaccine, vol. 25, no. 8, pp. 1513-25, 2007.
, “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.”, J Infect Dis, vol. 194, no. 12, pp. 1638-49, 2006.
, “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.”, J Infect Dis, vol. 194, no. 12, pp. 1650-60, 2006.
,